Clinical distribution and drug resistance of ESBLs-producing and non ESBLs-producing Escherichia coli isolated from 2014 to 2015
10.3969/j.issn.1673-4130.2017.15.006
- VernacularTitle:2014-2015年ESBLs阳性和ESBLs阴性大肠埃希菌临床分布及其耐药性的分析
- Author:
Haiyan GONG
;
Shaoyu LI
;
Shanshan YANG
;
Xuehan WANG
- Keywords:
Escherichia coli;
distribution;
drug resistance;
extended-spectrum β-lactamase
- From:
International Journal of Laboratory Medicine
2017;38(15):2030-2033
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze clinical distribution and drug resistance of extended-spectrum β-lactamase(ESBLs)-producing and non ESBLs-producing Escherichia coli(E.coli) isolated from 2014 to 2015.Methods Collected 4 721 clinical specimens from January 2014 to December 2015,separated and identified by using VITEK 2-Compact automatic microorganism identification and sensitivity analysis system of Biomerieux,France.Results A total of 1 181 E.coli were isolated from 4 721 clinical specimens,the isolation rate was 25.02%,and the isolation rates of 2014 and 2015 were 17.38% and 19.24% respectively.Meanwhile,the isolation rates of ESBLs-producing E.coli from 2014 and 2015 were 44.46% and 51.71%,increased 7.25%.For the ESBLs-producing E.coli,the main specimens from urine,sputum,blood,appendix content,pus and secreta,and general surgery department,pneumology department,urology,Neurosurgery departments were the main infection departments.For the non ESBLs-producing E.coli,the main specimens from urine,blood,sputum,appendix content,pus and secreta.The drug resistance of E.coli to antibiotics showed increasingly upward trend from 2014 to 2015.However,it showed high sensitive to amikacin,imipenem and meropenem.Conclusion As the isolation rate of E.coli increased in 2015,so does the drug resistance,and it is need combine with the actual situation of medication to regulate the usage of antibiotics.
